Hospital costs directly related to management of healthcare-associated infections (HAIs) are on the rise and the subject of intense focus for managing quality of care and institutional efficiency.
Additionally, the US acute care costs associated with Clostridioides difficile (C. difficile), formerly Clostridium difficile, infection are up to $5.9 billion.1 On top of these financial costs, HAIs can result in2:
- Prolonged hospital stays
- Increased resistance of microorganisms to antimicrobials
- Emotional burden for patients and their families
- Increased number of deaths
- Decreased hospital reputation3